Ratings on (GBL) (GTXI) (HEOP) (KNDL) (KWK) Upgraded

Ratings on Gamco Investors Inc. (NYSE: GBL), GTx, Inc. (NASDAQ: GTXI), Heritage Oaks Bancorp (NASDAQ: HEOP), Kendle International (NASDAQ: KNDL) and Quicksilver Resources Inc (NYSE: KWK) upgraded by analysts.

Bank of America (NYSE:BAC) upgraded Gamco Investors Inc. (GBL) from a “neutral” rating to a “buy” rating. They have a price target of $61.00 on the company.

Lazard Capital upgraded GTx, Inc. (GTXI) from a “neutral” rating to a “buy” rating. They now have a price target of $8.00 on the company.

Raymond James upgraded Heritage Oaks Bancorp (HEOP) from an “underperform” rating to a “market perform” rating.

Raymond James upgraded Kendle International (KNDL) from an “underperform” rating to a “market perform” rating.

Global Hunter Securities upgraded Quicksilver Resources Inc (KWK) from a “neutral” rating to a “buy” rating. They have a price target of $17.50 on the company, up from $17.00.

Ratings on (G) (JDSU) (KNDL) (MAC) (MFC) Upgraded

Ratings on Genpact Limited (NYSE: G), JDS Uniphase Co. (NASDAQ: JDSU), Kendle International (NASDAQ: KNDL), The Macerich Company (NYSE: MAC) and Manulife Financial (NYSE: MFC) were upgraded by analysts today.

BGB Securities upgraded Genpact Limited (G) from a “sell” rating to a “hold” rating. They have a price target of $16.00 on the company, up from $11.00.

Argus upgraded JDS Uniphase Co. (JDSU) from a “hold” rating to a “buy” rating. They have a price target of $27.00 on the company.

Goldman Sachs (NYSE:GS) upgraded Kendle International (KNDL) from a “sell” rating to a “neutral” rating.

Keefe, Bruyette & Woods, Inc upgraded The Macerich Company (MAC) from a “market perform” rating to an “outperform” rating. They have a price target of $58.00 on the company.

RBC Capital upgraded Manulife Financial (MFC) from a “sector perform” rating to an “outperform” rating. They have a price target of $19.00 on the company.

Why Amylin Pharmaceuticals (AMLN), Kendle International (KNDL), Sigma Designs (SIGM) Got Crushed Last Week

Amylin Pharmaceuticals (Nasdaq:AMLN), Kendle International (Nasdaq:KNDL) and Sigma Designs (Nasdaq:SIGM) got hammered last week, falling from 13.07 percent to 25.38 percent in one day.

This is an all too familiar and distasteful feeling for investors in Amylin Pharmaceuticals. Back in October, they got crushed when Amylin lost almost half its market value after the FDA rejected its diabetes drug Bydureon, saying the drug needed more testing.

So yesterday, Amylin and partners Eli Lilly (NYSE:LLY) and Alkermes announced results from a new clinical trial against Novo Nordisk's (NYSE:NVO) Victoza (which weren't part of the regulatory process) and came up short. Apparently, way short. While the pharmaceutical still plans to resubmit its application to market Bydureon for the third time, investors aren't waiting around again.

Clinical research organization Kendle International sold off sharply yesterday over the big fourth-quarter loss it reported, reversing a year-ago profit, and it's down another 11% this morning.

Sigma's on board with Motorola Mobility (MMI), Cisco (Nasdaq:CSCO), and others, and Sigma-based boxes for IPTV solutions are expanding. There's no reason to think Sigma Designs won't be laughing at this plunge later.






Full Story